Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. (2s)-n-((1s)-1-benzyl-2-(((1s)-3-methyl-1-(((2r)-2-methyloxiran-2-yl)carbonyl)butyl)amino)-2-oxoethyl)-4-methyl-2-(((2s)-2-((morpholin-4-ylacetyl)amino)-4-phenylbutanoyl)amino)pentanamide
2. Kyprolis
3. Pr-171
4. Pr171
1. 868540-17-4
2. Kyprolis
3. Carfilzomib (pr-171)
4. Pr-171
5. Carfilzomib (pr171)
6. Unii-72x6e3j5ar
7. Nsc-758252
8. 72x6e3j5ar
9. Chembl451887
10. Chebi:65347
11. Ncgc00249613-01
12. Dsstox_cid_28616
13. Dsstox_rid_82886
14. Dsstox_gsid_48690
15. (2s)-4-methyl-n-[(2s)-1-[[(2s)-4-methyl-1-[(2r)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]-2-[[(2s)-2-[(2-morpholin-4-ylacetyl)amino]-4-phenylbutanoyl]amino]pentanamide
16. (2s)-n-((1s)-1-benzyl-2-(((1s)-3-methyl-1-(((2r)-2-methyloxiran-2-yl)carbonyl)butyl)amino)-2-oxoethyl)-4-methyl-2-(((2s)-2-((morpholin-4-ylacetyl)amino)-4-phenylbutanoyl)amino)pentanamide
17. (alphas)-alpha-[[2-(4-morpholinyl)acetyl]amino]benzenebutanoyl-l-leucyl-n-[(1s)-3-methyl-1-[[(2r)-2-methyl-2-oxiranyl]carbonyl]butyl]-l-phenylalaninamide
18. (s)-4-methyl-n-((s)-1-(((s)-4-methyl-1-((r)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)-2-((s)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamide
19. N-{(2s)-2-[(morpholin-4-ylacetyl)amino]-4-phenylbutanoyl}-l-leucyl-n-{(2s)-4-methyl-1-[(2r)-2-methyloxiran-2-yl]-1-oxopentan-2-yl}-l-phenylalaninamide
20. (s)-4-methyl-n-((s)-1-((s)-4-methyl-1-((r)-2-methyloxiran-2-yl)-1-oxopentan-2-ylamino)-1-oxo-3-phenylpropan-2-yl)-2-((s)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamide
21. Carfilzomib [usan]
22. Cas-868540-17-4
23. Carfilzomib [usan:inn]
24. Mfcd11040997
25. Kyprolis (tn)
26. Carfilzomib; Pr171
27. Carfilzomib [mi]
28. Carfilzomib [inn]
29. Carfilzomib [jan]
30. Carfilzomib [vandf]
31. Schembl85165
32. Carfilzomib [who-dd]
33. Mls006011102
34. Carfilzomib (jan/usan/inn)
35. Gtpl7420
36. Dtxsid4048690
37. Amy4357
38. Carfilzomib [orange Book]
39. Ex-a2037
40. Ono-7057
41. Tox21_113079
42. Bdbm50277889
43. Nsc756640
44. Nsc758252
45. S2853
46. Zinc49841054
47. Akos025401910
48. Tox21_113079_1
49. Ccg-270405
50. Cs-0984
51. Cs-w004540
52. Db08889
53. Nsc 758252
54. Nsc-756640
55. Ncgc00249613-02
56. Ncgc00249613-03
57. Ncgc00249613-08
58. Ncgc00249613-11
59. Ncgc00249613-13
60. Ac-27051
61. As-17059
62. Hy-10455
63. Smr004660024
64. Sw218090-2
65. D08880
66. Ab01565867_02
67. Sr-01000941582
68. J-501773
69. Sr-01000941582-1
70. Q15366934
71. (alphas)-alpha-((4-morpholinylacetyl)amino)benzenebutanoyl-l-leucyl-n-((1s)-3-methyl-1-(((2r)-2-methyloxiranyl)carbonyl)butyl)-l-phe Nylalaninamide
72. (s)-4-methyl-n-((s)-1-((s)-4-methyl-1-((r)-2- Methyloxiran-2-yl)-1 -oxopentan-2-ylamino)-1-oxo-3-phenylpropan-2-yl)-2-((s)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamide
73. L-phenylalaninamide, (.alpha.s)-.alpha.-((4-morpholinylacetyl)amino)benzenebutanoyl-l-leucyl-n-((1s)-3-methyl-1-(((2r)-2-methyloxiranyl)carbonyl)butyl)-
74. L-phenylalaninamide, (alphas)-alpha-((4-morpholinylacetyl)amino)benzenebutanoyl-l-leucyl-n-((1s)-3-methyl-1-(((2r)-2-methyloxiranyl)carbonyl)butyl)-
Molecular Weight | 719.9 g/mol |
---|---|
Molecular Formula | C40H57N5O7 |
XLogP3 | 4.7 |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 8 |
Rotatable Bond Count | 20 |
Exact Mass | 719.42579917 g/mol |
Monoisotopic Mass | 719.42579917 g/mol |
Topological Polar Surface Area | 159 Ų |
Heavy Atom Count | 52 |
Formal Charge | 0 |
Complexity | 1180 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 5 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 2 | |
---|---|
Drug Name | Kyprolis |
PubMed Health | Carfilzomib (Injection) |
Drug Classes | Antineoplastic Agent |
Drug Label | KYPROLIS (carfilzomib) for Injection is an antineoplastic agent available for intravenous use only. KYPROLIS is a sterile, white to off-white lyophilized powder and is available as a single-use vial. Each vial of KYPROLIS contains 60mg of carfilzom... |
Active Ingredient | Carfilzomib |
Dosage Form | Powder |
Route | Intravenous |
Strength | 60mg/vial |
Market Status | Prescription |
Company | Onyx Pharms |
2 of 2 | |
---|---|
Drug Name | Kyprolis |
PubMed Health | Carfilzomib (Injection) |
Drug Classes | Antineoplastic Agent |
Drug Label | KYPROLIS (carfilzomib) for Injection is an antineoplastic agent available for intravenous use only. KYPROLIS is a sterile, white to off-white lyophilized powder and is available as a single-use vial. Each vial of KYPROLIS contains 60mg of carfilzom... |
Active Ingredient | Carfilzomib |
Dosage Form | Powder |
Route | Intravenous |
Strength | 60mg/vial |
Market Status | Prescription |
Company | Onyx Pharms |
Carfilzomib is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with lenalidomide and dexamethasone; or dexamethasone; or daratumumab and dexamethasone; or daratumumab and hyaluronidase-fihj and dexamethasone. It is also indicated as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.
FDA Label
Kyprolis in combination with daratumumab and dexamethasone, with lenalidomide and dexamethasone, or with dexamethasone alone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
Treatment of Multiple Myeloma
Treatment of acute lymphoblastic leukaemia
Intravenous carfilzomib administration resulted in suppression of proteasome chymotrypsin-like activity when measured in blood 1 hour after the first dose. On Day 1 of Cycle 1, proteasome inhibition in peripheral blood mononuclear cells (PBMCs) ranged from 79% to 89% at 15 mg/m2, and from 82% to 83% at 20 mg/m2. In addition, carfilzomib administration resulted in inhibition of the LMP2 and MECL1 subunits of the immunoproteasome ranging from 26% to 32% and 41% to 49%, respectively, at 20 mg/m2. Proteasome inhibition was maintained for 48 hours following the first dose of carfilzomib for each week of dosing. Resistance against carfilzomib has been observed and although the mechanism has not been confirmed, it is thought that up-regulation of P-glycoprotein may be a contributing factor. Furthermore, studies suggest that carfilzomib is more potent than bortezomib.
L01XX45
L01XX45
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
L - Antineoplastic and immunomodulating agents
L01 - Antineoplastic agents
L01X - Other antineoplastic agents
L01XG - Proteasome inhibitors
L01XG02 - Carfilzomib
Absorption
Cmax, single IV dose of 27 mg/m^2 = 4232 ng/mL; AUC, single IV dose of 27 mg/m^2 = 379 nghr/mL; Carfilzomib does not accumulation in the systemic. At doses between 20 and 36 mg/m2, there was a dose-dependent increase in exposure.
Volume of Distribution
Vd, steady state, 20 mg/m^2 = 28 L
Clearance
Systemic clearance = 151 - 263 L/hour. As this value exceeds hepatic blood flow, it suggests that carfilozmib is cleared extrahepatically.
Carfilzomib was rapidly and extensively metabolized by the liver. The predominant metabolites were the peptide fragments and the diol of carfilzomib which suggests that the main metabolic pathways are peptidase cleavage and epoxide hydrolysis. The cytochrome P450 enzyme system is minimally involved in the metabolism of carfilzomib. All metabolites are inactive.
Following intravenous administration of doses 15 mg/m^2, carfilzomib was rapidly cleared from the systemic circulation with a half-life of 1 hour on Day 1 of Cycle 1.
Carfilzomib is made up of four modified peptides and acts as a proteasome inhibitor. Carfilzomib irreversibly and selectively binds to N-terminal threonine-containing active sites of the 20S proteasome, the proteolytic core particle within the 26S proteasome. This 20S core has 3 catalytic active sites: the chymotrypsin, trypsin, and caspase-like sites. Inhibition of the chymotrypsin-like site by carfilzomib (5 and 5i subunits) is the most effective target in decreasing cellular proliferation, ultimately resulting in cell cycle arrest and apoptosis of cancerous cells. At higher doses, carfilzomib will inhibit the trypsin-and capase-like sites.
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : Reviewed
Rev. Date : 2016-07-06
Pay. Date : 2016-05-04
DMF Number : 30402
Submission : 2016-03-29
Status : Active
Type : II
Date of Issue : 2022-06-06
Valid Till : 2025-07-07
Written Confirmation Number : WC-0039
Address of the Firm :
NDC Package Code : 55111-985
Start Marketing Date : 2016-03-29
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
GDUFA
DMF Review : Reviewed
Rev. Date : 2024-09-19
Pay. Date : 2024-08-27
DMF Number : 32406
Submission : 2017-12-30
Status : Active
Type : II
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Tofigh Daru develops & synthesizes a diverse range of APIs in Anticancer, Narcotics, Cardiovascular to Immunomodulatory Segments.
Chunghwa provides cost-effective APIs & advanced intermediates with complete DMF or COS, ensuring quality & reliable production.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 31276
Submission : 2016-12-30
Status : Active
Type : II
NDC Package Code : 52076-6251
Start Marketing Date : 2012-10-16
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Omgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.
GDUFA
DMF Review : Reviewed
Rev. Date : 2016-02-25
Pay. Date : 2015-12-21
DMF Number : 30124
Submission : 2016-01-21
Status : Active
Type : II
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : Complete
Rev. Date : 2016-07-06
Pay. Date : 2016-05-04
DMF Number : 30402
Submission : 2016-03-29
Status : Active
Type : II
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
GDUFA
DMF Review : Complete
Rev. Date : 2024-09-19
Pay. Date : 2024-08-27
DMF Number : 32406
Submission : 2017-12-30
Status : Active
Type : II
Chunghwa provides cost-effective APIs & advanced intermediates with complete DMF or COS, ensuring quality & reliable production.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 31276
Submission : 2016-12-30
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 30162
Submission : 2015-12-29
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 29750
Submission : 2016-01-30
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2020-10-09
Pay. Date : 2020-09-01
DMF Number : 35083
Submission : 2020-09-08
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2016-04-19
Pay. Date : 2016-01-20
DMF Number : 30115
Submission : 2016-03-22
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2015-11-16
Pay. Date : 2015-09-23
DMF Number : 29671
Submission : 2015-08-29
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 30357
Submission : 2016-02-26
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2016-02-05
Pay. Date : 2015-09-25
DMF Number : 29770
Submission : 2015-09-28
Status : Active
Type : II
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
(S)-2-((S)-4-methyl-2-((S)-2-(2-morpholinoacetamid...
CAS Number : 868540-16-3
End Use API : Carfilzomib
About The Company : Cohance Lifesciences is a leading CDMO and API platform, offering products and services across all phases of a molecule’s lifecycle from development to commer...
(S)-2-amino-4-methyl-1-((R)-2-methyloxiran-2-yl)pe...
CAS Number : 247068-85-5
End Use API : Carfilzomib
About The Company : Cohance Lifesciences is a leading CDMO and API platform, offering products and services across all phases of a molecule’s lifecycle from development to commer...
(alphaS)-alpha-[(4-Morpholinylacetyl)aMino]benzene...
CAS Number : 868540-16-3
End Use API : Carfilzomib
About The Company : Established in 2011 and situated in Hangzhou, Zhejiang, China, Hangzhou Longshine Bio-Tech CO., Ltd is dedicated to providing services for pharmaceutical and ch...
Morpholin-4-yl-acetic acid Hydrochloride
CAS Number : 89531-58-8
End Use API : Carfilzomib
About The Company : Established in 2011 and situated in Hangzhou, Zhejiang, China, Hangzhou Longshine Bio-Tech CO., Ltd is dedicated to providing services for pharmaceutical and ch...
tert-Butyl {(2S)-4-methyl-1-[(2R)-2-methyloxiran-2...
CAS Number : 247068-82-2
End Use API : Carfilzomib
About The Company : Established in 2011 and situated in Hangzhou, Zhejiang, China, Hangzhou Longshine Bio-Tech CO., Ltd is dedicated to providing services for pharmaceutical and ch...
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Regulatory Info : RX
Registration Country : USA
Brand Name : CARFILZOMIB
Dosage Form : POWDER;INTRAVENOUS
Dosage Strength : 60MG/VIAL
Packaging :
Approval Date : 2019-09-09
Application Number : 209422
Regulatory Info : RX
Registration Country : USA
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Regulatory Info : Lead Market Dossiers- Filed
Registration Country : India
Brand Name :
Dosage Form : Injection
Dosage Strength : 60MG/VIAL
Packaging :
Approval Date :
Application Number :
Regulatory Info : Lead Market Dossiers- Filed
Registration Country : India
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Regulatory Info : Lead Market Dossiers- Approved in US
Registration Country : India
Brand Name :
Dosage Form : Injection
Dosage Strength : 60MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : Lead Market Dossiers- Approved in US
Registration Country : India
Regulatory Info : DISCN
Registration Country : USA
Brand Name : CARFILZOMIB
Dosage Form : POWDER;INTRAVENOUS
Dosage Strength : 10MG/VIAL
Packaging :
Approval Date : 2021-06-11
Application Number : 209330
Regulatory Info : DISCN
Registration Country : USA
Regulatory Info : DISCN
Registration Country : USA
Brand Name : CARFILZOMIB
Dosage Form : POWDER;INTRAVENOUS
Dosage Strength : 60MG/VIAL
Packaging :
Approval Date : 2021-06-11
Application Number : 209330
Regulatory Info : DISCN
Registration Country : USA
Regulatory Info :
Registration Country : Iran
Brand Name : Filzoma
Dosage Form : Vial
Dosage Strength : 60MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Iran
Omgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Injection
Dosage Strength : 10MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Omgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Injection
Dosage Strength : 30MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Omgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Injection
Dosage Strength : 60MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Regulatory Info :
Registration Country : Switzerland
Brand Name : Kyprolis
Dosage Form : Dry Sub
Dosage Strength : 10mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
RLD : No
TE Code : AP
Brand Name : CARFILZOMIB
Dosage Form : POWDER;INTRAVENOUS
Dosage Strength : 60MG/VIAL
Approval Date : 2019-09-09
Application Number : 209422
RX/OTC/DISCN : RX
RLD : No
TE Code : AP
RLD : No
TE Code :
Brand Name : CARFILZOMIB
Dosage Form : POWDER;INTRAVENOUS
Dosage Strength : 10MG/VIAL
Approval Date : 2021-06-11
Application Number : 209330
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code :
Brand Name : CARFILZOMIB
Dosage Form : POWDER;INTRAVENOUS
Dosage Strength : 60MG/VIAL
Approval Date : 2021-06-11
Application Number : 209330
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code :
Brand Name : CARFILZOMIB
Dosage Form : POWDER;INTRAVENOUS
Dosage Strength : 60MG/VIAL
Approval Date : 2020-03-16
Application Number : 209425
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD :
TE Code :
Brand Name : CARFILZOMIB
Dosage Form : POWDER;INTRAVENOUS
Dosage Strength : 60MG/VIAL
Approval Date :
Application Number : 210823
RX/OTC/DISCN :
RLD :
TE Code :
RLD :
TE Code :
Brand Name : CARFILZOMIB
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 10MG
Approval Date :
Application Number : 209526
RX/OTC/DISCN :
RLD :
TE Code :
RLD :
TE Code :
Brand Name : CARFILZOMIB
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 30MG
Approval Date :
Application Number : 209526
RX/OTC/DISCN :
RLD :
TE Code :
RLD :
TE Code :
Brand Name : CARFILZOMIB
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 60MG
Approval Date :
Application Number : 209526
RX/OTC/DISCN :
RLD :
TE Code :
RLD : Yes
TE Code :
Brand Name : KYPROLIS
Dosage Form : POWDER;INTRAVENOUS
Dosage Strength : 30MG/VIAL
Approval Date : 2016-06-03
Application Number : 202714
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD : Yes
TE Code :
Brand Name : KYPROLIS
Dosage Form : POWDER;INTRAVENOUS
Dosage Strength : 10MG/VIAL
Approval Date : 2018-06-07
Application Number : 202714
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
Regulatory Info :
Registration Country : Australia
Brand Name : Kyprolis
Dosage Form :
Dosage Strength :
Packaging : 1
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Kyprolis
Dosage Form :
Dosage Strength :
Packaging : 1
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Kyprolis
Dosage Form :
Dosage Strength :
Packaging : 1
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Kyprolis
Dosage Form :
Dosage Strength :
Packaging : 1
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Kyprolis
Dosage Form :
Dosage Strength :
Packaging : 1
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Kyprolis
Dosage Form :
Dosage Strength :
Packaging : 1
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Kyprolis
Dosage Form :
Dosage Strength :
Packaging : 1
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Kyprolis
Dosage Form :
Dosage Strength :
Packaging : 1
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Kyprolis
Dosage Form :
Dosage Strength :
Packaging : 1
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Kyprolis
Dosage Form :
Dosage Strength :
Packaging : 1
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info : Originator
Registration Country : South Africa
Brand Name : Kyprolis
Dosage Form : Inj
Dosage Strength : 60mg
Packaging : 1X50mg
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Regulatory Info : Lead Market Dossiers- Filed
Registration Country : India
Brand Name :
Dosage Form : Injection
Dosage Strength : 60MG/VIAL
Packaging :
Approval Date :
Application Number :
Regulatory Info : Lead Market Dossiers- Filed
Registration Country : India
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Packaging :
Regulatory Info : Lead Market Dossiers- Filed
Dosage : Injection
Dosage Strength : 60MG/VIAL
Brand Name :
Approval Date :
Application Number :
Registration Country : India
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Regulatory Info : Lead Market Dossiers- Approved...
Registration Country : India
Brand Name :
Dosage Form : Injection
Dosage Strength : 60MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : Lead Market Dossiers- Approved...
Registration Country : India
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Packaging :
Regulatory Info : Lead Market Dossiers- Approved...
Dosage : Injection
Dosage Strength : 60MG
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Regulatory Info :
Registration Country : Iran
Brand Name : Filzoma
Dosage Form : Vial
Dosage Strength : 60MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Iran
Packaging :
Regulatory Info :
Dosage : Vial
Dosage Strength : 60MG
Brand Name : Filzoma
Approval Date :
Application Number :
Registration Country : Iran
Omgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Injection
Dosage Strength : 10MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Omgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.
Packaging :
Regulatory Info :
Dosage : Injection
Dosage Strength : 10MG
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Omgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Injection
Dosage Strength : 30MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Omgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.
Packaging :
Regulatory Info :
Dosage : Injection
Dosage Strength : 30MG
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Omgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Injection
Dosage Strength : 60MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Omgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.
Packaging :
Regulatory Info :
Dosage : Injection
Dosage Strength : 60MG
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Injection
Dosage Strength : 60MG
Packaging : 50ml + WFI
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Packaging : 50ml + WFI
Regulatory Info :
Dosage : Injection
Dosage Strength : 60MG
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Regulatory Info :
Registration Country : India
Brand Name : ERLOTED
Dosage Form : Injection
Dosage Strength : 25mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Packaging :
Regulatory Info :
Dosage : Injection
Dosage Strength : 25mg
Brand Name : ERLOTED
Approval Date :
Application Number :
Registration Country : India
Regulatory Info :
Registration Country : India
Brand Name : ERLOTED
Dosage Form : Injection
Dosage Strength : 50mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Packaging :
Regulatory Info :
Dosage : Injection
Dosage Strength : 50mg
Brand Name : ERLOTED
Approval Date :
Application Number :
Registration Country : India
Regulatory Info :
Registration Country : India
Brand Name : ERLOTED
Dosage Form : Injection
Dosage Strength : 100mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Packaging :
Regulatory Info :
Dosage : Injection
Dosage Strength : 100mg
Brand Name : ERLOTED
Approval Date :
Application Number :
Registration Country : India
Related Excipient Companies
Excipients by Applications
Dosage Form : Capsule, Injectable / Parenteral, Nasal Solution, Ophthalmic Solution, Tablet, Topical Film
Grade : Parenteral, Oral, Ophthalmic...
Category : Dry Powder Inhalation, Emulsifying Agents, Parenteral, Solubilizers, Taste Masking, Thickeners and Stabilizers
Application : Dry Powder Inhalation, Emulsifying Agents, Parenteral, Solubilizers, Taste Masking, Thickeners and Stabilizers
Pharmacopoeia Ref : USP NF
Technical Specs : Captisol® is a polyanionic beta-cyclodextrin derivative with a s...
Ingredient(s) : Betadex Sulfobutyl Ether Sodium Excipient
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?